Journal article icon

Journal article

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

Abstract:

Background: Trastuzumab targets the extracellular domain of the HER2 protein. Adding trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer reduces the risk of recurrence and death, but is associated with cardiac toxicity. We investigated the long-term benefits and risks of adjuvant trastuzumab on breast cancer recurrence and cause-specific mortality.

Methods: We did a collaborative meta-analysis of individual patien...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/S1470-2045(21)00288-6

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Sub department:
Clinical Trial Service Unit
Role:
Author
ORCID:
0000-0003-4440-574X
Expand authors...

Contributors

Publisher:
Elsevier Publisher's website
Journal:
Lancet Oncology Journal website
Volume:
22
Issue:
8
Pages:
1139-1150
Publication date:
2021-08-01
Acceptance date:
2021-05-07
DOI:
EISSN:
1474-5488
ISSN:
1470-2045
Language:
English
Keywords:
Pubs id:
1177831
Local pid:
pubs:1177831
Deposit date:
2021-05-21

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP